MWNA
SCMP

Marshall Wace North America’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Marshall Wace North America’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,773
Closed -$357K – 1783
2017
Q3 		$357K Sell
29,773
-66,767
-69% -$749K ﹤0.01% 1117
2017
Q2 		$1.06M Buy
+96,540
New +$984K 0.01% 921

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Marshall Wace North America's SCMP Position: Q4 2017 in Review

Marshall Wace North America sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 29,773 shares — an estimated $357K sold.

Marshall Wace North America first reported a position in SCMP in Q2 2017 and held it in 2 quarters. The position peaked at $1.06M in Q2 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Marshall Wace North America reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 29,773 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $357K.
  • Marshall Wace North America first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Marshall Wace North America's Sucampo Pharmaceuticals, Inc. position peaked at $1.06M in Q2 2017.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.